

**For immediate release**

**23 November 2006**

**Proximagen Neuroscience plc**

("Proximagen" or "the Company")

**MINI-SYMPOSIUM AND PIPELINE UPDATE**

London, UK, 23 November 2006 □ Proximagen Neuroscience plc (AIM: PRX), the drug discovery and development company focused on neurodegenerative diseases, is pleased to announce that it is holding its second annual mini-symposium on Neurodegenerative Disease and giving a pipeline update today. The mini-symposium will take place at the Company □s offices near London Bridge from 4.45pm to 7pm.

Short presentations will be given by the following speakers: Kenneth Mulvany, Chief Executive, Proximagen; Professor Niall Quinn, National Hospital for Neurology and Neurosurgery, London; Dr Ray Chaudhuri, King □s College Hospital, London; Tom Isaacs, Founder of □Movers and Shakers □; Professor Peter Jenner, Chief Scientific Officer, Proximagen; Ray Hill, Executive Director and Head, Licensing and External Research, Europe, Merck, Sharp and Dohme and Dr Bruce Campbell, Chairman, Proximagen.

**Commenting on the mini-symposium and Proximagen □s pipeline, Kenneth Mulvany, Chief Executive Officer of Proximagen, said:**

"We are delighted to be hosting the second annual mini-symposium on neurodegenerative diseases with such a prestigious line-up of guest speakers. The event aims to provide an insight into the impact on patients of diseases such as Parkinson □s and Alzheimer □s and to highlight the potential of Proximagen □s in-house R&D pipeline which is focused on developing new and more effective therapies for these patients.

Proximagen has made measured progress across each of its programmes since last year's symposium and we have generated some exciting data.

Work on our lead programme, PRX1, for improving the symptomatic treatment of Parkinson □s disease, has identified four compounds that exhibit exciting characteristics when compared to current treatments. We look forward to updating shareholders on our research findings."

**Ends**

**For more information, or an invitation to today □s meeting, please contact:**

**Proximagen Neuroscience plc** ([www.proximagen.com](http://www.proximagen.com))

Kenneth Mulvany, Chief Executive Officer

020 7848 6938

James Hunter, Finance Director

**Buchanan Communications**

Tim Anderson / Mary-Jane Johnson/ Catherine Breen

020 7466 5000